Methods and products for treating pseudomonas infection
AssigneeThe Brigham and Women's Hospital, Inc.
InventorGerald B. Pier
Life of this patent
Estimating the term…
Abstract
Methods and products for upregulating cystic fibrosis transmembrane conductance regulators are provided, including methods and products for the treatment of P. aeruginosa infection. The products include polysaccharides that interact with the cystic fibrosis transmembrane conductance regulator (CFTR). The polysaccharide compositions of the invention may be administered to a subject in order to enhance the uptake of P. aeruginosa into the epithelial cells of the subject. The invention also encompasses compositions comprising a lipopolysaccharide-binding region of a CFTR linked to an anti-Pseudomal drug and methods of use of such compositions. Compositions and methods for gene therapy are also disclosed. The compositions include polysaccharides that bind to CFTR coupled to a gene delivery vehicle.
Claims28
A pharmaceutical preparation comprising
- a CFTR expression regulator, wherein the CFTR expression regulator is free of lipid A and is a polysaccharide that is an LPS core moiety comprising
- wherein X is selected from the group consisting of glucose, glucose-rhamnose and H;
- wherein Y is selected from the group consisting of rhamnose and H;
- and
- wherein Z is selected from the group consisting of glucose and H;
- and
- a pharmaceutically acceptable carrier.
A pharmaceutical preparation comprising
- a CFTR expression regulator, wherein the CFTR expression regulator is free of lipid A and is a polysaccharide that is an LPS core moiety comprising
- wherein X is selected from the group consisting of glucose, glucose-rhamnose and H;
- wherein Y is selected from the group consisting of rhamnose and H;
- and
- wherein Z is selected from the group consisting of glucose and H;
- and
- a pharmaceutically acceptable carrier.
A pharmaceutical preparation comprising
- a CFTR expression regulator, wherein the CFTR expression regulator is free of lipid A and is a polysaccharide that is an LPS core moiety comprising
- wherein X is selected from the group consisting of glucose, glucose-rhamnose and H;
- wherein Y is selected from the group consisting of rhamnose and H;
- and
- wherein Z is selected from the group consisting of glucose and H;
- and
- a pharmaceutically acceptable carrier.
A pharmaceutical preparation comprising
- a CFTR expression regulator, wherein the CFTR expression regulator is free of lipid A and is a polysaccharide that is an LPS core moiety comprising
- wherein X is selected from the group consisting of glucose, glucose-rhamnose and H;
- wherein Y is selected from the group consisting of rhamnose and H;
- and
- wherein Z is selected from the group consisting of glucose and H;
- and
- a pharmaceutically acceptable carrier.
A composition of matter comprising
- a covalent conjugate of a non-toxic lipid for associating a bioactive agent with a polysaccharide, wherein the non-toxic lipid is not lipid A and a polysaccharide comprising
- wherein X is selected from the group consisting of glucose, glucose-rhamnose and H;
- Y is selected from the group consisting of rhamnose and H;
- and Z is selected from the group consisting of glucose and H.
A composition of matter comprising
- a covalent conjugate of a bioactive agent wherein the bioactive agent is not lipid A and a polysaccharide comprising
- wherein X is selected from the group consisting of glucose, glucose-rhamnose and H;
- Y is selected from the group consisting of rhamnose and H;
- and Z is selected from the group consisting of glucose and H.
Dependencies are inferred from the claim text.